-
Actavis Inc., the largest U.S. maker of generic drugs by market value, agreed to acquire Warner Chilcott Plc for about $5 billion excluding net debt in a deal to expand in women’s health and urology.
-
Teva Pharmaceutical Industries Ltd. resumes trading today in Tel Aviv at the biggest discount to New York in 2 1/2 years after the prospect of acquisitions among generic-drug makers fueled gains in its U.S.-traded stock.
-
Actavis Inc., the generic drugmaker whose merger negotiations with Valeant Pharmaceuticals International Inc. stalled over price, may deserve the industry’s second-best valuation ever in a deal.
-
Traders are betting that a bidding war for anti-aging cream maker Obagi Medical Products Inc. isn’t over yet.
-
Impax Laboratories Inc. declined the most in more than two months after the company failed to win U.S. approval for an extended-release formulation of a Parkinson’s disease drug used to relieve spasms in patients.
-
Impax Laboratories Inc. failed to win U.S. approval for a new version of an extended-release drug used to relieve spasms in patients with Parkinson’s disease.
-
Elan Corp.’s impending cash influx will give the drug developer leeway to buy something it lacks: a product.
-
Medicis Pharmaceutical Corp., the maker of wrinkle treatments and acne drugs, fell the most in almost five months in New York trading after the girlfriend of millionaire founder and Chief Executive Officer Jonah Shacknai was found dead yesterday at the executive’s beachside home.
-
Questcor Pharmaceuticals Inc. fell the most in 20 years after insurer Aetna Inc. said it would limit coverage of the company’s top-selling drug. The drugmaker said it doesn’t expect a “material impact” from the change.
-
Valeant Pharmaceuticals International Inc.’s $2.6 billion agreement to buy skin-care company Medicis Pharmaceutical Corp. recharges an acquisition plan that stumbled with last year’s failed bid for Cephalon Inc.
Rate this Page